Cenegermin
| Clinical data | |
|---|---|
| Trade names | Oxervate |
| Other names | Recombinant human nerve growth factor; rhNGF, cenegermin-bkbj |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619001 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C583H908N166O173S8 |
| Molar mass | 13267.15 g·mol−1 |
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor.[4] Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).[4]
The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.[5]
It was approved for medical use in the European Union in July 2017,[5] and in the United States in 2018.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]
Medical uses
[edit]Cenegermin is indicated for the treatment of neurotrophic keratitis.[4][5]
Society and culture
[edit]Names
[edit]Cenegermin is the international nonproprietary name.[7] It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli.[7]
Cenegermin is sold under the brand name Oxervate.[4][5]
References
[edit]- ^ "AusPAR: Cenegermin". Therapeutic Goods Administration (TGA). 23 December 2019. Archived from the original on 1 November 2021. Retrieved 26 August 2020.
- ^ "Oxervate APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
- ^ "Summary Basis of Decision (SBD) for Oxervate". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ a b c d e f "Oxervate- cenegermin-bkbj kit; Oxervate- cenegermin-bkbj solution/ drops". DailyMed. 8 October 2024. Retrieved 26 October 2024.
- ^ a b c d e "Oxervate EPAR". European Medicines Agency (EMA). Retrieved 25 August 2020.
- ^ a b New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.
- ^ a b World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1): 76. hdl:10665/330984.
Further reading
[edit]- Deeks ED, Lamb YN (April 2020). "Cenegermin: A Review in Neurotrophic Keratitis". Drugs. 80 (5): 489–494. doi:10.1007/s40265-020-01289-w. PMID 32185680.
- Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, et al. (January 2020). "Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial". Ophthalmology. 127 (1): 14–26. doi:10.1016/j.ophtha.2019.08.020. PMID 31585826.
- Sheha H, Tighe S, Hashem O, Hayashida Y (October 2019). "Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis". Clin Ophthalmol. 13: 1973–1980. doi:10.2147/OPTH.S185184. PMC 6789413. PMID 31631965.
